Albany, NY -- (SBWIRE) -- 03/26/2018 -- Cellular therapy, also known as cytotherapy, is a therapy in which cellular material is injected into a patient. For example, T cells, capable of showing a cell mediated immune response, are injected into a cancer patient during immunotherapy. Cellular therapy is used in the treatment of different types of disorders and diseases. The main approach for cellular therapy in oncology involves infusion of immune cells either to replace most of the patient's immune system to enhance his immune response to cancer or to activate his cell mediated immune system to kill the cancer cells, or to directly find and kill the targeted cancer cells. Presently, multiple cell-based approaches are ongoing in clinical phase I through phase III testing in patients diagnosed with different types of cancer.

Read Report Overview: https://www.transparencymarketresearch.com/cellular-therapy-oncology-pipeline-market.html

According to the World Health Organization (WHO), around 8.2 million people die annually from cancer, worldwide. Rise in the prevalence rate of cancer due to lack of adequate treatment is the major reason fuelling the growth of the global cellular therapy in oncology pipeline market. Cell therapy trials are presently ongoing which are in various phases. Cellular therapy is said to have advantage over gene therapy; recently, scientists have developed innovative therapies by combining both cell and gene therapies. Moreover, dendritic cell therapy is another promising development in the treatment of cancer. These are some of the drivers of the global cellular therapy in oncology pipeline market during the forecast period. Recently developed immunotherapies representing a variety of mechanisms of actions, such as novel agents targeting proteins or cell surface markers, are in the phase of clinical trials, is another factor that is expected to propel the growth of the global cellular therapy in oncology pipeline market during the forecast period. However, high cost of therapies, development of biosimilars and drugs for prevention and treatment of cancer, and stringent regulatory scenario are anticipated to be the key restraints to the growth of the global cellular therapy in oncology pipeline market during the forecast period.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40703

The global cellular therapy in oncology pipeline market can be segmented on the basis of clinical phase, type of mechanism of action, and geography. The global cellular therapy market, based on clinical phase, can be divided into research, preclinical, clinical phase I, clinical phase I/II, clinical phase II, and clinical phase III. In terms of type of mechanism of action, the global cellular therapy in oncology pipeline market can be classified into targeting signaling pathways, targeting cell surface markers, targeting miRNA expression, and others. Targeting the signaling pathway is a promising mechanism and is expected to register high growth in the global cellular therapy in oncology pipeline market.

Geographically, the global cellular therapy in oncology pipeline market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global cellular therapy in oncology pipeline market during the forecast period owing to developed research infrastructure, high prevalence of cancer, strong funding for oncology research, etc. Asia Pacific is anticipated to exhibit significant growth in the global cellular therapy in oncology pipeline market due to the factors such as developing research domain, rise in awareness among people regarding treatment of cancer, and high prevalence of cancer on the region.

Request TOC of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=40703

Major global players operating in the global cellular therapy in oncology pipeline market include Aldagen, apceth Biopharma GmbH, Benitec Biopharma Limited, Argos Therapeutics, CELGENE CORPORATION, Immunocellular Therapeutics, Ltd, GALENA BIOPHARMA, pluristem Commence Bio, and Kite Pharma. To sustain a significant position in the global cellular therapy in oncology pipeline market, these players have been adopting strategies such as developing highly efficient and cost-effective products. Recently, certain companies have also developed a sophisticated automated device for cell expansion and culture processing which can be used in the treatment of different types of cancer.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About Transparency Market Research
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/